Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Moderate Buy” by Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $94.20.

PBH has been the topic of a number of recent research reports. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 28th.

Prestige Consumer Healthcare Stock Up 1.7 %

Prestige Consumer Healthcare stock opened at $69.58 on Friday. The company has a market capitalization of $3.46 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.93 and a beta of 0.47. The firm’s fifty day simple moving average is $70.92 and its 200-day simple moving average is $69.31. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 1-year low of $56.61 and a 1-year high of $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. The business had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.06 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Covestor Ltd grew its position in Prestige Consumer Healthcare by 21.6% in the 1st quarter. Covestor Ltd now owns 834 shares of the company’s stock worth $61,000 after purchasing an additional 148 shares during the last quarter. Evergreen Capital Management LLC grew its position in Prestige Consumer Healthcare by 5.4% in the 2nd quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock worth $216,000 after purchasing an additional 160 shares during the last quarter. Miller Howard Investments Inc. NY grew its position in Prestige Consumer Healthcare by 2.2% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after purchasing an additional 165 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the last quarter. Finally, QRG Capital Management Inc. grew its position in Prestige Consumer Healthcare by 4.7% in the 2nd quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock worth $372,000 after purchasing an additional 242 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.